Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination pharmaceutical used for the **treatment of cough and respiratory disorders** associated with excessive or thick mucus, such as bronchitis, bronchial asthma, emphysema, and chronic obstructive pulmonary disease. - **Bromhexine** is a mucolytic agent that thins and loosens mucus in the airways, making it easier to expel. - **Guaifenesin** acts as an expectorant by increasing the hydration of secretions and decreasing their viscosity, aiding in the clearance of mucus. - **Menthol** provides a sensation of coolness and relieves minor throat irritation by its local soothing effects. - **Terbutaline** is a bronchodilator that relaxes airway smooth muscle via beta-2 adrenergic receptor agonism, making breathing easier and helping to relieve bronchospasm. It is most often formulated as a **syrup for oral administration** and is indicated for productive cough where bronchospasm and mucus plugging co-exist[1][2][5][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bromhexine + guaifenesin + menthol + terbutaline.